Abbas Kazimi
@AbbasRKazimi
Followers
375
Following
2K
Media
11
Statuses
193
Chief Business Officer @NimbusTx. Biotech transactor & drug discovery enabler in the hope of getting patients better medicines. Tweets are solely my own views.
Cambridge, MA
Joined April 2011
After a ~decade of discovery & rigorous development, our TYK2 inhibitor found an inheritor to deliver our molecule to patients around the globe. Thrilled to welcome @TakedaPharma to the @NimbusTx journey and excited to see the path that lies ahead for our therapy🧵.
Today @TakedaPharma and Nimbus announced a definitive agreement under which Takeda will acquire Nimbus’ highly selective, allosteric TYK2 inhibitor:
1
0
27
RT @KRHornberger: There’s a frequent perception among recent entrants to drug discovery world that if we could just find drug candidates fa….
0
107
0
0
2
0
RT @JebKeiper: Honored to kickoff the Private Track at #jpm2024 (7:30am Monday!!) with new programs in immunology and data updates on other….
linkedin.com
Honored to kickoff the Private Track presentations at #jpm2024 at 7:30am Monday with exciting disclosures on two new immunology programs in the Nimbus Therapeutics pipeline, along with additional...
0
3
0
Humbled to join Timmerman Traverse in Feb '24 to climb Mt. Kilimanjaro & raise $50K for @DamonRunyon. I have lost family & friends to cancer & supporting research provides important breakthroughs for medicines. Please help me achieve my goal here:
secure.qgiv.com
0
2
8
After 14 years, our mission to design breakthrough medicines continues! Thank you to our incredible investors for believing in Nimbus and our collective passion to change the course of treatment for patients. Excited to welcome @GVteam to join us on our journey.
We’re excited to announce a $210 million private financing to advance our next wave of tech-enabled small molecule medicines. Learn more:
0
0
5
So fortunate to be nominated by @BiotechWkBoston and have our #TYK2 transaction with @TakedaPharma recognized. Looking forward to spending the evening with our Nimbi & Takeda colleagues!.
We are honored to be a finalist for @BiotechWkBoston’s Deal of the Year Award, recognizing the acquisition of our TYK2 inhibitor by Takeda, one of the largest single asset deals in all of biotech.
0
0
6
RT @JebKeiper: Great @BrianPGormley @WSJ article today on getting back to returns in biotech; appreciate the @NimbusTx mention https://t.c….
wsj.com
Regulatory scrutiny of acquisitions could slow momentum.
0
1
0
RT @NimbusTx: This week, Nimbus' Director of Computational Chemistry, Leela Dodda, will present at the Gordon Research Conference on Medici….
0
2
0
- Series A investments picking-up [oncology leads, though different modalities given IRA impact on smols]. - Licensing deals down: biotech turns to licensing when weak public market; buyers are tougher than ever on terms - need better deal structures and long-term wins.
0
0
2
Thanks @ChrisDoko & @DealForma for the rich analysis covering 1H'23. Some takeaways:. - M&A picking-up for late-stage assets (Ph2+); interesting to see how recent FTC & continued IRA uncertainty impacts 2H ‘23
1
3
7
'Know thyself'. So important for biotech's to know their role (target ID, disc., devp't., comm'l, etc.) in getting medicines to patients. Helps to articulate to investors, partners, and employees their business plan, and keeps the entire organization focused on a mission.
Investigating the origins of recent pharmaceutical innovation An analysis of new drugs from the top 20 biopharma companies indicates that their business model in recent years has largely been built on external innovation, as only 28% originated internally
0
0
4
While the 'how' is important in drug discovery, focusing on the 'what' comes out of of the approach matters (insert @Dereklowe). Lots of hype indeed and a self-created race to be the first "AI" drug in the clinic. not sure why, but if patients benefit, that is the winner.
New: I talked with Schrödinger CEO Ramy Farid about entering a dangerous moment of AI hype in biotech:. "To me, describing ourselves as a machine-learning company would be like describing ourselves as a company that uses Microsoft Office.”.
0
1
2
RT @BiotechTVHQ: Big deals and small molecules with Nimbus Therapeutics CEO @JebKeiper. Full video: .
0
9
0
RT @AndyBiotech: "The exception is more interesting than the rule.".#Biotech reverse merger occasionally turn into >$1B buyout. Aduro➡️ $KD….
0
13
0
RT @NimbusTx: Tomorrow, our Nimbi will participate in @BioBall_MA 2023, an annual basketball event to benefit @SpOlympicsMA. This is your l….
0
2
0
Aspirations to industrialize drug discovery is commendable & worth pursuing.@NimbusTx has seen its path to success through refining target selection & integrating compchem / AI tools at the right time. Lot of humility gained over 14 years to design breakthrough medicines!.
Artificial intelligence could be key to unlocking the next big breakthrough in medicine, and it’s already helping human researchers develop new drugs much faster
1
0
2
RT @NimbusTx: Next week, Nimbus CBO @AbbasRKazimi will participate in the Keynote panel on M&A and Strategic Financing in Today's Biotech T….
0
2
0
RT @OHSUKnight: At the 2023 Stanford Drug Discovery Symposium, Dr. Brian Druker discussed his groundbreaking work proving it was possible t….
genengnews.com
The Lifetime Achievement Awardee at the 2023 Stanford Drug Discovery Symposium shared his journey to discovering Imatinib (Gleevec).
0
6
0
RT @LifeSciVC: "The Book of Nimbus" - with @NimbusTx becoming 14 years old in May, CEO @JebKeiper shares some history and frames up our evo….
0
12
0
Many thanks to all our Nimbi, investors, collaborators and of course patients – all absolutely critical to the success of our #TYK2 journey!.
Results from the Phase 2b clinical trial of TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus and owned by Takeda, in patients with moderate-to-severe plaque psoriasis were presented at the 2023 @AADskin Annual Meeting:
0
0
2